These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36827494)

  • 1. Typology of Users of Psychedelics and Alike Psychoactive Substances in Czechia: Results of the National Online Survey.
    Kňažek F; Horák M; Ocetková T; Somerlíková K; Bláhová B; Plevková M; Mravčík V; Chomynová P; Kočárová R
    J Psychoactive Drugs; 2023; 55(5):601-611. PubMed ID: 36827494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of psychedelics in the Czech Republic: results of recent population surveys.
    Chomynová P; Kočárová R; Kňažek F; Plevková M; Bláhová B; Valeš K; Mravčík V
    Cent Eur J Public Health; 2022 Sep; 30(3):144-153. PubMed ID: 36239361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations.
    Soussan C; Kjellgren A
    Int J Drug Policy; 2016 Jun; 32():77-84. PubMed ID: 27184218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contextual Parameters Associated with Positive and Negative Mental Health in Recreational Psychedelic Users.
    St Arnaud KO; Sharpe D
    J Psychoactive Drugs; 2023; 55(1):30-39. PubMed ID: 35156542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Need for Psychiatric Treatment among Polish Users of Psychoactive Substances Is Increasing: This and Other Results from the Newest PolDrugs Survey.
    Więckiewicz G; Marek J; Stokłosa I; Szafoni S; Pluta S; Smukowska K; Żebrowska G; Stokłosa M; Gorczyca P; Pudlo R
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241141
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemsex users in Czechia: EMIS survey.
    Uholyeva X; Pitoňák M
    Cent Eur J Public Health; 2022 Jun; 30(2):86-92. PubMed ID: 35876596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing self-reported use of new psychoactive substances: The impact of gate questions.
    Palamar JJ; Acosta P; Calderón FF; Sherman S; Cleland CM
    Am J Drug Alcohol Abuse; 2017 Sep; 43(5):609-617. PubMed ID: 28485987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COgnitive enhancement and consumption of psychoactive Substances among Youth Students (COSYS): a cross-sectional study in France.
    Batisse A; Leger S; Vicaut E; Gerbaud L; Djezzar S
    Public Health; 2021 May; 194():75-78. PubMed ID: 33865150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
    Soussan C; Andersson M; Kjellgren A
    Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motives and Side-Effects of Microdosing With Psychedelics Among Users.
    Hutten NRPW; Mason NL; Dolder PC; Kuypers KPC
    Int J Neuropsychopharmacol; 2019 Jul; 22(7):426-434. PubMed ID: 31152167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why psychiatry needs psychedelics and psychedelics need psychiatry.
    Sessa B
    J Psychoactive Drugs; 2014; 46(1):57-62. PubMed ID: 24830186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results.
    Butler M; Seynaeve M; Bradley-Westguard A; Bao J; Crawshaw A; Pick S; Edwards M; Nicholson T; Rucker J
    J Neuropsychiatry Clin Neurosci; 2023; 35(1):77-85. PubMed ID: 35578800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.
    Kuc J; Kettner H; Rosas F; Erritzoe D; Haijen E; Kaelen M; Nutt D; Carhart-Harris RL
    Psychopharmacology (Berl); 2022 May; 239(5):1425-1440. PubMed ID: 34734314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Mental Health across Distinct Groups of Users of Psychedelics, MDMA, Psychostimulants, and Cannabis.
    Rougemont-Bücking A; Jungaberle H; Scheidegger M; Merlo MCG; Grazioli VS; Daeppen JB; Gmel G; Studer J
    J Psychoactive Drugs; 2019; 51(3):236-246. PubMed ID: 30836844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturalistic Psychedelic Use: A World Apart from Clinical Care.
    Glynos NG; Fields CW; Barron J; Herberholz M; Kruger DJ; Boehnke KF
    J Psychoactive Drugs; 2023; 55(4):379-388. PubMed ID: 35950817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between lifetime classic psychedelic use and markers of physical health.
    Simonsson O; Sexton JD; Hendricks PS
    J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.
    Deligianni E; Daniel OJ; Corkery JM; Schifano F; Lione LA
    Br J Clin Pharmacol; 2020 Mar; 86(3):505-516. PubMed ID: 31495968
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.